Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
Community
/
Brazil
/
Pharmaceuticals & Biotech
Create a narrative
Hypera
BOVESPA:HYPE3 Community
1
Narratives
written by author
0
Comments
on narratives written by author
7
Fair Values set
on narratives written by author
Create a narrative
Hypera
Popular
Undervalued
Overvalued
Hypera
AN
Analyst Price Target
Consensus Narrative from 13 Analysts
Product Expansion And Investments In Chronic Treatments Will Strengthen Future Operations
Key Takeaways Hypera's working capital focus will improve cash flow, enhancing net margins and financial stability through inventory and operational efficiency enhancements. Product diversification and increased capacity in key therapeutic areas are set to drive growth despite unchanged marketing and innovation investment strategies.
View narrative
R$25.72
FV
22.0% undervalued
intrinsic discount
14.75%
Revenue growth p.a.
Set as Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
2 days ago
author updated this narrative
Your Valuation for
HYPE3
Hypera
Your Fair Value
R$
Current Price
R$20.06
0.4% undervalued
intrinsic discount
Growth estimate over
Annual revenue growth rate
5 Years
time period
%/yr
Decrease
Increase
Past
Future
0
13b
2015
2018
2021
2024
2025
2027
2030
Revenue R$13.3b
Earnings R$2.4b
Advanced
Set as Fair Value